Title: IMAGING-BASED DIAGNOSIS OF SARCOPENIA FOR TRANSPLANT-FREE
SURVIVAL IN PRIMARY SCLEROSING CHOLANGITIS
Version: 3 Date: 03 Apr 2024
Reviewer's report:
Some comments are listed as follows:
1.According to the second question from Reviewer #1, the authors should explain the impact of
sarcopenia on the outcome of PSC recipients after liver transplantation, the authors said “…we
cannot adequately respond to the question as this would require a liver transplantation control
group without PSC”. But a liver transplantation control group without sarcopenia is needed to
respond to the question.
2.According to the second question for the methods part form Reviewer #2, the authors said
“The ethical approval to conduct this study was given in 2018 by the local ethics committee
but the retrospective data collection only occurred in spring 2022”. The authors should collect
patients’data until 2018 because this is a retrospective study and the ethical approval was given
in 2018, or get new ethical approval which is given after 2022.
3.According to the first question in major comments part from Reviewer #3, the authors said
“To prevent further confusion, we do not indicate CP Grades for non-cirrhotic patients and have
revised table 1 accordingly”. There are 48 liver cirrhosis patients, but Child-Pugh Grades are
listed for 45 patients in the table 1. Please revise your data carefully.
4.According to the fourth question in major comments part from Reviewer #3, the authors should
explain the difference and connection between myosteatosis and loss of muscle mass, rather
than myosteatosis and sarcopenia.
5.In the supplementary Figure 10 and Figure 13, the numbers “0” and “1” should be revised as
words “no liver cirrhosis” and “liver cirrhosis” respectively.
Title: IMAGING-BASED DIAGNOSIS OF SARCOPENIA FOR TRANSPLANT-FREE
SURVIVAL IN PRIMARY SCLEROSING CHOLANGITIS
Version: 3 Date: 03 Apr 2024
Reviewer's report:
Some comments are listed as follows:
1.According to the second question from Reviewer #1, the authors should explain the impact of
sarcopenia on the outcome of PSC recipients after liver transplantation, the authors said “…we
cannot adequately respond to the question as this would require a liver transplantation control
group without PSC”. But a liver transplantation control group without sarcopenia is needed to
respond to the question.
2.According to the second question for the methods part form Reviewer #2, the authors said
“The ethical approval to conduct this study was given in 2018 by the local ethics committee
but the retrospective data collection only occurred in spring 2022”. The authors should collect
patients’data until 2018 because this is a retrospective study and the ethical approval was given
in 2018, or get new ethical approval which is given after 2022.
3.According to the first question in major comments part from Reviewer #3, the authors said
“To prevent further confusion, we do not indicate CP Grades for non-cirrhotic patients and have
revised table 1 accordingly”. There are 48 liver cirrhosis patients, but Child-Pugh Grades are
listed for 45 patients in the table 1. Please revise your data carefully.
4.According to the fourth question in major comments part from Reviewer #3, the authors should
explain the difference and connection between myosteatosis and loss of muscle mass, rather
than myosteatosis and sarcopenia.
5.In the supplementary Figure 10 and Figure 13, the numbers “0” and “1” should be revised as
words “no liver cirrhosis” and “liver cirrhosis” respectively.
Please review this paper.
user
Title: IMAGING-BASED DIAGNOSIS OF SARCOPENIA FOR TRANSPLANT-FREE
SURVIVAL IN PRIMARY SCLEROSING CHOLANGITIS
Version: 3 Date: 03 Apr 2024
Reviewer's report:
Some comments are listed as follows:
1.According to the second question from Reviewer #1, the authors should explain the impact of
sarcopenia on the outcome of PSC recipients after liver transplantation, the authors said “…we
cannot adequately respond to the question as this would require a liver transplantation control
group without PSC”. But a liver transplantation control group without sarcopenia is needed to
respond to the question.
2.According to the second question for the methods part form Reviewer #2, the authors said
“The ethical approval to conduct this study was given in 2018 by the local ethics committee
but the retrospective data collection only occurred in spring 2022”. The authors should collect
patients’data until 2018 because this is a retrospective study and the ethical approval was given
in 2018, or get new ethical approval which is given after 2022.
3.According to the first question in major comments part from Reviewer #3, the authors said
“To prevent further confusion, we do not indicate CP Grades for non-cirrhotic patients and have
revised table 1 accordingly”. There are 48 liver cirrhosis patients, but Child-Pugh Grades are
listed for 45 patients in the table 1. Please revise your data carefully.
4.According to the fourth question in major comments part from Reviewer #3, the authors should
explain the difference and connection between myosteatosis and loss of muscle mass, rather
than myosteatosis and sarcopenia.
5.In the supplementary Figure 10 and Figure 13, the numbers “0” and “1” should be revised as
words “no liver cirrhosis” and “liver cirrhosis” respectively.
assistant